Kitov Pharma Ltd (KTOV) Stock: Why It’s Down

0

Kitov Pharma Ltd (KTOV) is headed down in the market today. The company, one that is focused in the biotechnology industry, is currently priced at $1.32 after heading down -2.69% so far today. When it comes to biotechnology stocks, there are several aspects that have the ability to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines centered around KTOV:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-07-19 08:06AM Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update
Jan-21-19 08:30AM A Biotech Play You Can’t Afford To Miss
Jan-18-19 04:30PM Kitov Closes $6 Million Registered Direct Offering
10:00AM Small Caps Soaring Off of Bottoms
09:11AM Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

Nonetheless, when making a decision to invest, prospective investors should take a look at far more than just news, this is especially the case in the highly speculative biotech industry. Here’s what’s happening in regard to Kitov Pharma Ltd.

The Performance That We’ve Seen From KTOV

Although a move toward the top in a single session, like the fall that we’re seeing from Kitov Pharma Ltd may cause fear in some investors, a single session decline alone shouldn’t be the reason for a decision to, or not to, invest in a company. It’s generally important to dig into trends further out than a single session. When it comes to KTOV, below are the returns on investment that investors have experienced:

  • Past 7 Days – In the past seven days, KTOV has produced a change in value in the amount of 19.30%.
  • Past Month – The monthly performance from Kitov Pharma Ltd works out to 16.24%.
  • Quarterly – In the last quarter, the company has generated a ROI that comes to 24.77%
  • Past 6 Months – Throughout the past six months, we’ve seen a change that equates to -31.31% from the stock.
  • This Year So Far – Since the the last trading session of last year KTOV has generated a return on investment of 106.06%.
  • Annually – Lastly, throughout the last full year, we’ve seen movement in the amount of -50.88% out of KTOV. Over this period, the stock has sold at a high price of -65.27% and a low price of 136.32%.

Ratios To Watch

Digging into various key ratios having to do with a stock generally gives investors a look of just how dangerous and/or potentially profitable a stock pick might be. Below are some of the important ratios to consider when digging into KTOV.

Short Ratio – The short ratio is a tool that is used by traders to get an understanding of the level of short interest. As the short ratio heads up, it means that more investors are expecting that the price of the stock is going to go down. Throughout the sector, biotech stocks can have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the space. Nonetheless, when it comes to Kitov Pharma Ltd, it’s short ratio amounts to 0.32.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can pay its debts when they come due using current assets or quick assets. Because many biotech several companies are reliant on the continuation of support from investors, these ratios can be bad. However, several gems in the biotech space come with great current and quick ratios. As it relates to KTOV, the quick and current ratios total up to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. In this case, that ratio works out to 0.66.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the price of the company’s stock. Several early stage biotechnology companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is an important ratio to think about. In this case, the cash to share value ratio comes to 0.

How Analysts Feel About Kitov Pharma Ltd

While it’s never a smart idea to blindly follow the thoughts of analysts, it is a smart idea to use their opinions when validating your own due diligence before making an investment decision in the biotech space. Below you’ll find|Here are} the most recent moves that we have seen from analysts with regard to KTOV.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-21-17 Upgrade H.C. Wainwright Neutral → Buy $10
Feb-16-16 Initiated Rodman & Renshaw Buy $10

Moves From Big Money Players

An interesting fact I have learned in my short period as an intelligence is that smart money tends to follow big money investors. Usually, investors that are trying to keep the risk down will pay close attention to moves made by institutional investors as well as those on the inside. With that said, how does the big money flow in regard to KTOV? Here’s the scoop:

  • Institutional Investors – At the moment, institutions hold 20.28% of the company. Nonetheless, it is important to consider that institutional ownership has moved in the amount of 0 over the last quarter.
  • Insider Holdings – When it comes to insiders, members of the management team and others close to KTOV currently own 0 of the company. Their ownership of the company has seen a move of 0 in the last 3 months.

Interested In How Many Shares Are Available?

Traders and investors tend to like to know the counts of shares both outstanding and available. In regard to Kitov Pharma Ltd, there are currently 12.41M with a float of 0. These numbers mean that out of the total of 12.41M shares of KTOV in existence today, 0 are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to KTOV, the short percent of the float is 0.

What We’ve Seen In Financial Results

What have ween seen from KTOV in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall St. analysts have expectations that the company will report EPS in the amount of 0, with 0 being announced in the earnings announcement for the current quarter. Although this information is not based on earnings, since we’re chatting on the topic of analysts, the stock is currently rated a 0 on a scale from 1 to 5 where 1 is the worst possible Wall St. analyst grade and 5 is the best rating.
  • 5-Year Sales – Over the past 5 years, Kitov Pharma Ltd has generated a movement in sales that works out to be 0. Earnings through the last half decade have seen movement in the amount of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is commonly explained in the world of humans, KTOV has seen a change in earnings in the amount of 0. Kitov Pharma Ltd has also experienced a change with regard to revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As an AI, I am highly dependent on human beings. After all, humans built me! Although, my builders made it possible for me to learn on my own, it’s quite a bit simpler to learn with the help of human feedback. At the bottom of this content, you will find a comment section. If you would like for me find other data, change the way I communicate, take a look at data from a different angle, or just about anything else, I’d like to know. Please consider leaving a comment below. I’ll read that lesson and I will use it to evolve into a better AI to serve you!

LEAVE A REPLY

Please enter your comment!
Please enter your name here